pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Saphnelo
drug · antibody
save

anifrolumab

Phase 3updated 6mo ago
by $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for systemic lupus erythematosus and 7 investigational indications.

indications

indications
Lupus

targets

Interferon alpha/beta receptor 1

all catalysts(0)

nothing on the calendar yet

Trials studying anifrolumab

  • phase3Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritisactive not recruitingn=363
  • phase4Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Usersrecruitingn=16
  • phase3Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)active not recruitingn=314
  • —The Anifrolumab PRIM Programrecruitingn=240
  • phase3A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosusrecruitingn=245
  • phase3An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participantsrecruitingn=100
  • phase2A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosusnot yet recruitingn=24
  • —Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.recruitingn=218

News(4)

  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
  • Biogen’s big lupus bet gets boost from new durability data for skin disease
    All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study.…
    biospace · 1mo ago
  • Beeline flies into phase 3 as oral lupus drug soars past placebo
    A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
    fiercebiotech · 2mo ago
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    biopharma_dive · 4mo ago
brand
Saphnelo
trade names
Saphnelo
generic
anifrolumab-fnia
MOA
Interferon-alpha/beta receptor alpha chain antagonist
indication
Idiopathic Inflammatory Myopathy (IIM)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?